- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01910142
Effect of Nutrition on Bone Metabolism as Assessed by 41Ca
July 26, 2013 updated by: Henk FJ Hendriks, TNO
The Effect of Nutritional Intervention on Bone Metabolism as Assessed by 41Ca and Modeling; Proof of Concept
The present study aims to develop a technique based on a single dose of a calcium isotope, which enables to determine the effect of a nutritional intervention on bone calcium metabolism.
For this purpose nutritional interventions with calcium, vitamin D and vitamin K will be applied in postmenopausal women.
Treatment effects will be determined by the urinary excretion of the calcium isotope and related to classical bone markers.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
In the present proposal a method is described that may enable studying the effect of nutrition on bone calcium turnover far more accurate, within a shorter time frame and therefore less intensive for the volunteers in clinical studies as compared to presently existing methods.
This method will enable screening for promising food concepts for combating osteoporosis within a relatively short time.
Recent developments show that use of the nuclide 41Calcium (41Ca) and measurement by accelerator mass spectrometry (AMS) has great potential in measuring effects on bone level within a relatively short period of time.
When introducing a diet change (intervention) the bone metabolism of calcium may change resulting in a changed 41Ca-signal in the urine.
So far a few medication studies with osteoporotic volunteers have been performed and it appears that this ultrahigh sensitive technique may also be applicable for nutrition studies in healthy volunteers.
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 68 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
Healthy as assessed by the
- health and lifestyle questionnaire,
- physical examination
- results of the pre-study laboratory tests
- Females aged 50-68 years at Day 01 of the study
- Relatively low calcium intake as assessed by dairy intake questionnaire
- Body Mass Index (BMI) < 30 kg/m2
- Postmenopausal as confirmed by Follicle stimulating hormone (FSH) and oestradiol (E2) blood levels (FSH > 40IU/L, E2 < 70 pg/mL)
- Normal Dutch eating habits
- Voluntary participation
- Having given written informed consent
- Willing to comply with the study procedures
- Appropriate veins for blood sampling/cannula insertion according to TNO
- Willing to accept use of all nameless data, including publication, and the confidential use and storage of all data for at least 15 years
- Willing to accept the disclosure of the financial benefit of participation in the study to the authorities concerned.
Exclusion Criteria:
- Participation in any clinical trial including blood sampling and/or administration of substances up to 90 days before Day 01 of this study
- Participation in any non-invasive clinical trial up to 30 days before Day 01 of this study, including no blood sampling and/or oral, intravenous, inhalatory administration of substances
- Having a history of medical or surgical events that may significantly affect the study outcome, including cardiovascular disease or hypertension and gastrointestinal disease
- Prescribed medication, including hormone replacement therapy (within 6 months before start of the study) and anticoagulant medication.
- Reported intolerance for dairy products
- Not willing to stop the use of Boerenkarnemelk and cheese of the following Dutch brands: Emmenthaler, Gruyere, Leer/Maasdammer
- Alcohol consumption > 21 units/week
- Not willing to stop use of supplements containing minerals or vitamins
- Reported unexplained weight loss or gain of > 2 kg in the month prior to the pre-study screening
- Reported slimming or medically prescribed diet
- Reported vegan, vegetarian or macrobiotic
- Recent blood donation (<1 month prior to the start of the study)
- Not willing to give up blood donation during the study.
- Personnel of TNO Quality of Life, their partner and their first and second degree relatives
- Not having a general practitioner
- Not willing to accept information-transfer concerning participation in the study, or information regarding her health, like laboratory results, findings at anamnesis or physical examination and eventual adverse events to and from her general practitioner.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: calcium supplement with vitamin K
Milk product supplying about 420 mg Ca and 7.5 μg vitamin D3 and 100 μg vitamin K.
Additional 200 mg calcium in the form of carbonate
|
A calcium product will be given either with or without vitamin K.
Each intervention will last for 5 weeks, each followed by a 5 week wash-out.
The first intervention will start about 4 months after inclusion and the single 41Ca bolus.
|
Placebo Comparator: calcium supplement without vitamin K
Milk product supplying about 420 mg Ca and 7.5 μg vitamin D3. no vitamin K.
Additional 200 mg calcium in the form of carbonate
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
urinary 41calcium excretion
Time Frame: on study day numbers: 36, 71, 106, 113, 120, 127, 134, 141, 148, 155, 162, 169, 176, 183, 190, 197, 204, 211, 218, 225, 232, 239, 246, 253, 260, 267, 274, 281, 288
|
Urine is collected for measurement of 41Ca.
The concentration change of 41Ca during the intervention period indicates the efficacy of the intervention.
|
on study day numbers: 36, 71, 106, 113, 120, 127, 134, 141, 148, 155, 162, 169, 176, 183, 190, 197, 204, 211, 218, 225, 232, 239, 246, 253, 260, 267, 274, 281, 288
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
commonly accepted biomarkers for bone metabolism
Time Frame: on study day numbers: 148, 183, 218, 253, 288
|
Plasma osteocalcin and urinary deoxypyridinolin/creatinin ratio are measured as traditional markers for bone accretion and bone resorption respectively.
These are the most commonly used biomarkers for bone metabolism.
|
on study day numbers: 148, 183, 218, 253, 288
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Gertruud C Bakker, PhD, TNO
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2008
Primary Completion (Actual)
August 1, 2009
Study Completion (Actual)
August 1, 2009
Study Registration Dates
First Submitted
April 9, 2010
First Submitted That Met QC Criteria
July 26, 2013
First Posted (Estimate)
July 29, 2013
Study Record Updates
Last Update Posted (Estimate)
July 29, 2013
Last Update Submitted That Met QC Criteria
July 26, 2013
Last Verified
July 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Metabolic Diseases
- Musculoskeletal Diseases
- Bone Diseases
- Bone Diseases, Metabolic
- Osteoporosis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Fibrin Modulating Agents
- Micronutrients
- Vitamins
- Calcium-Regulating Hormones and Agents
- Antifibrinolytic Agents
- Hemostatics
- Coagulants
- Vitamin K
- Calcium
Other Study ID Numbers
- 8145
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoporosis
-
Radius Health, Inc.CompletedOsteoporosis | Osteoporosis Risk | Osteoporosis, Postmenopausal | Osteoporosis Fracture | Osteoporosis, Age-Related | Osteoporosis Localized to Spine | Osteoporosis Senile | Osteoporosis of Vertebrae | Osteoporosis VertebralUnited States
-
Radius Health, Inc.CompletedOsteoporosis | Age Related Osteoporosis | Osteoporosis, Age-Related | Osteoporosis Localized to Spine | Osteoporosis Senile | Osteoporosis of VertebraeUnited States, Poland, Italy
-
Hoffmann-La RocheCompletedPostmenopausal OsteoporosisUnited States
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisUnited States, Puerto Rico
-
Centre Hospitalier Universitaire de Saint EtienneMinistry of Health, FranceRecruitingPost Menopausal OsteoporosisFrance
-
AmgenCompletedPost Menopausal OsteoporosisFrance
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisUnited States
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisSpain, South Africa, Germany, Mexico, United States, Canada, France, United Kingdom, Italy, Belgium, Australia, Poland, Denmark, Hungary, Czech Republic, Norway
-
Hoffmann-La RocheGlaxoSmithKlineCompletedPost Menopausal OsteoporosisFrance
-
Novartis PharmaceuticalsCompletedPost-menopausal OsteoporosisColombia, Belgium, Sweden, Hong Kong, United States, Hungary, Switzerland, Australia, Germany, Italy, Canada, Poland, Argentina, Thailand, Norway, New Zealand, France, Finland
Clinical Trials on vitamin K
-
Ain Shams UniversityCompletedEnd Stage Renal Disease on DialysisEgypt
-
Maastricht University Medical CenterCompletedCarboxylation Level | Vitamin K-dependent ProteinsNetherlands
-
DaniscoCompleted
-
Maastricht University Medical CenterCompleted
-
HaEmek Medical Center, IsraelWithdrawn
-
RWTH Aachen UniversityCompleted
-
Institut de Recherches Cliniques de MontrealUniversité de MontréalWithdrawnCystic FibrosisCanada
-
Instituto Mexicano del Seguro SocialRodolfo Guardado Mendoza; Marco Antonio Ocampo Apolonio; Texar Alfonso Pereyra...CompletedCoronary CalcificationMexico
-
Guy's and St Thomas' NHS Foundation TrustUnknownPost-menopausal OsteoporosisUnited Kingdom
-
National and Kapodistrian University of AthensRecruitingAortic Valve Stenosis | Mitral Valve Stenosis | Aortic Valve Calcification | Mitral Annular Calcification | Mitral Valve CalcificationGreece